Pricing Log in Create free account
Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue
+27.0%
EPS
−40.3%
Free cash flow
−140.2%
Total debt
+4.46%

Quarter to September 2026, against a year earlier

25.13 0.90 −3.46%
Market cap
$7.4B
P/E
77.7×
Fwd P/E
254×
Dividend yield
—
F-score
n/a
Altman Z
3.55
Beneish M
−2.71
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Caris Life Sciences,�Inc. 8-K filed Jun 5, 2026

Period ended Jun 4, 2026 · Filed · accepted 5:03 PM ET · Document on sec.gov · Filing index

5.07 Submission of matters to a vote of security holders

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov